Propanc Biopharma earnings were -$19.8M for the trailing 12 months ending Jun 30, 2026, with N/A growth year over year. The latest PPCB earnings report on Jun 30, 2026 announced Q2 2026 earnings of -$4.6M, down 28.1% from last quarter. For the last reported fiscal year 2026 ending Jun 30, 2026, PPCB reported annual earnings of -$19.8M, with -66.4% growth. The next PPCB earnings date is Nov 13, 2026.
What were Propanc Biopharma's earnings last quarter?
Propanc Biopharma (NASDAQ: PPCB) reported Q2 2026 earnings per share (EPS) of $6.20, up 98.96% year over year. Total PPCB earnings for the quarter were -$4.57 million. In the same quarter last year, Propanc Biopharma's earnings per share (EPS) was $594.27.
The next PPCB earnings date is Nov 13, 2026. Add PPCB to your watchlist to be reminded of Propanc Biopharma's next earnings date.
What was PPCB's earnings growth in the past year?
As of Propanc Biopharma's earnings date in Q4 2026, Propanc Biopharma's earnings has grown year over year. PPCB earnings in the past year totalled -$19.79 million.
Is Propanc Biopharma profitable or losing money?
As of the last Propanc Biopharma earnings report, Propanc Biopharma is currently losing money. Propanc Biopharma's net profit (also called net income) for the twelve months ending Jun 30, 2026 was -$18.86 million, a 67.99% decrease year over year.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.